Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD
Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis
Bone. 2016 Aug;89:52-8A total of 27 randomized controlled trials were included in this network meta-analysis investigating the comparative efficacies of bisphosphonates - including alendronate, ibandronate, risedronate, and zoledronic acid - versus placebo or control in patients with low bone mineral density. All studied drugs demonstrated significant effects on vertebral fracture incidence and bone mineral density of the femoral neck; effects sizes of both outcomes were observed to be greatest with zoledronic acid. Ibandronate was the only drug to not demonstrate a significant effect on nonvertebral fracture incidence; risedronate demonstrated the greatest effect size.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
